David Gaffin, an officer at Alkermes plc, has filed a Form 144 to sell 2,035 shares of the company's common stock. The shares are valued at approximately $93,955.95 based on the recent market price. This transaction is part of Gaffin's ongoing management of his equity holdings in the company.

Alkermes plc, based in Dublin, is a company focused on pharmaceutical preparations. The recent filing, dated November 3, 2026, indicates that Gaffin's sale is part of a series of transactions he has conducted over the past months. This includes multiple sales of shares acquired through the vesting of restricted stock unit awards.

In the past three months alone, Gaffin has sold shares on several occasions, including sales of 2,034 shares on June 4, July 6, August 3, September 3, and October 2, 2026. The gross proceeds from these sales have varied, with the most recent transaction yielding nearly $94,000.

The pharmaceutical preparations sector, which Alkermes operates in, is characterized by significant competition and ongoing developments. Gaffin's actions may reflect broader trends among executives in the industry as they manage their stock holdings amidst market fluctuations.

As for what’s next, the filing does not specify any upcoming events or further actions related to this sale.